UnitedHealth, Cigna, CVS PBMs targeted by FTC over inflated insulin prices
The Federal Trade Commission has brought an administrative complaint against three of the country's largest pharmacy benefit managers (PBMs), accusing them of engaging in practices that artificially inflated the list price of insulin drugs.
Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...
CVS Health (NYSE:CVS) subsidiary Oak Street Health has reached a $60M settlement with the Department of Justice to resolve ...
The Anti-Kickback Statute prohibits anyone from offering or paying, directly or indirectly, money or anything else of value ...
Oak Street Health, a subsidiary of CVS, is paying $60 million to the federal government to resolve allegations that it ...
This week's dividend activity included increased payouts from Microsoft (NASDAQ:MSFT) and JPMorgan (NYSE:JPM) as well as ...
We recently compiled a list of the 10 Best Fortune 500 Stocks To Buy Now. In this article, we are going to take a look at ...
Oak Street Health – a key pillar of CVS Health’s (NYSE: CVS) health care services strategy – has reached a $60 million settlement with the Department of ...
CVS Health Corp. closed $24.83 short of its 52-week high ($83.25), which the company reached on January 8th.
The owner of one of the three largest pharmacy middlemen in the United States on Tuesday filed suit to quash an attempt by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback